Status:
UNKNOWN
Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
JW Pharmaceutical
Conditions:
Hip Fractures
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
This is a clinical trial to evaluate the effect of intravenous iron supplement with Ferinject (Ferric Carboxymaltose) in preventing postoperative delirium after hip fracture surgery.
Detailed Description
We hypothesized that IV iron supplement will (1) decrease postoperative delirium in hip fracture patients and (2) decrease the amount of transfusion and transfusion-related complications.
Eligibility Criteria
Inclusion
- femur neck fracture, intertrochanteric fractures
- Iron deficiency anemia (Hb\<12 in women, Hb\<13 in men)
- Iron deficiency (Serum ferritin \<100ug/L or transferrin saturation\<20%)
- Who understands this clinical trial and volunteers and agrees to this trial
Exclusion
- Patient under the age of 65 years
- Hb\<7 or someone who has acute symptom of anemia(tachycardia, dyspnea, or dizziness)
- High energy trauma
- Preoperative delirium
- MMSE\<10
- Underlying disease which involves cognitive dysfunction (e.g. neurovascular diseases, acute myocardial infarction, pulmonary embolism)
- Those who are inappropriate to participate in the clinical trial assessed by the investigators
Key Trial Info
Start Date :
July 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT05429749
Start Date
July 30 2020
End Date
December 31 2024
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam, South Korea, 13620